UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | April 4, 2005 (April 4, 2005) |
Endo Pharmaceuticals Holdings Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 001-15989 | | 13-4022871 |
| | | | | |
| | | | | |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 100 Endo Boulevard, Chadds Ford, PA | | 19317 |
| | | |
| | | |
| (Address of principal executive offices) | | (Zip Code) |
| | | |
| Registrant’s telephone number, including area code | | (610) 558-9800 |
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure.
On April 4, 2005, the Registrant intends to make a slide presentation at theCIBC World Markets Biotech and Specialty Pharma Conferencein New York, New York, a copy of which presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a)Financial Statements of Business Acquired.
Not applicable.
(b)Pro Forma Financial Information.
Not applicable.
(c)Exhibits.
| | | |
| Exhibit Number | | Description |
| 99.1 | | Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated April 4, 2005 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | | | | | | |
| | | ENDO PHARMACEUTICALS HOLDINGS INC. | | |
| | | | (Registrant) | | |
| | | | | | | |
| | By: | | /s/Carol A. Ammon | | |
| | | | | | |
| | | | Name: Carol A. Ammon | | |
| | | | Title: Chairman & Chief Executive Officer | | |
| | | | | | | |
| Dated: April 4, 2005 | | | | | | |
INDEX TO EXHIBITS
| | | |
| Exhibit No. | | Description |
| 99.1 | | Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated April 4, 2005 |
